|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003320,
umls-concept:C0017262,
umls-concept:C0019652,
umls-concept:C0026764,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0450442,
umls-concept:C0598864,
umls-concept:C1541478,
umls-concept:C1655731,
umls-concept:C1709059,
umls-concept:C1831850,
umls-concept:C1999216,
umls-concept:C2911684
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-4-15
|
|
pubmed:abstractText |
Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can be heterogeneous, leading to the potential for tumor escape despite MAGE-A3-induced immunity. We hypothesized that a combination of the hypomethylating agent 5-azacitidine (5AC) and the histone deacetylase inhibitor (HDACi) MGCD0103 (MGC) could induce MAGE-A3 expression in MAGE-A3-negative MM, resulting in recognition and killing of MM cells by MAGE-A3-specific cytotoxic T lymphocytes (CTL).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1477-2566
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
618-28
|
|
pubmed:meshHeading |
pubmed-meshheading:21171821-Antigens, Neoplasm,
pubmed-meshheading:21171821-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21171821-Azacitidine,
pubmed-meshheading:21171821-Benzamides,
pubmed-meshheading:21171821-Cell Line, Tumor,
pubmed-meshheading:21171821-DNA Methylation,
pubmed-meshheading:21171821-Epigenesis, Genetic,
pubmed-meshheading:21171821-Female,
pubmed-meshheading:21171821-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21171821-Histone Deacetylase Inhibitors,
pubmed-meshheading:21171821-Humans,
pubmed-meshheading:21171821-Male,
pubmed-meshheading:21171821-Multiple Myeloma,
pubmed-meshheading:21171821-Neoplasm Proteins,
pubmed-meshheading:21171821-Pyrimidines,
pubmed-meshheading:21171821-Recurrence,
pubmed-meshheading:21171821-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
|
|
pubmed:affiliation |
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
